Form 4: Guardant Health Chief Legal Officer Reports Routine Stock Transactions Under 10b5-1 Plan

Guardant Health's Chief Legal Officer, John G. Saia, reported the acquisition of common stock through RSU vesting and a concurrent sale for tax obligations, executed under a pre-arranged 10b5-1 plan.

Summary

• John G. Saia, Chief Legal Officer of Guardant Health, Inc. (GH), reported transactions involving the company's common stock.
• The transactions, dated June 15, 2025, were conducted pursuant to a Rule 10b5-1 trading plan, indicating they were pre-scheduled.
• Mr. Saia acquired 1,020 shares of common stock through the exercise of restricted stock units (RSUs).
• Concurrently, 535 shares of common stock were disposed of by the company to satisfy tax withholding obligations related to the RSU vesting, at a price of $49.29 per share.
• Following these reported transactions, Mr. Saia directly beneficially owns 43,568 shares of Guardant Health common stock.
• He also directly beneficially owns 4,078 restricted stock units.
• The restricted stock units involved in this transaction were part of an award granted on June 9, 2023, with 33% vesting on June 15, 2024, and the remaining 67% scheduled to vest in equal quarterly installments over the subsequent two-year period.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction related to executive compensation, with no significant positive or negative implications for the company's operational or financial performance.

Positives

• The vesting of restricted stock units indicates the achievement of performance or tenure milestones, reflecting value for the executive and aligning their interests with shareholders.
• The acquisition of 1,020 shares increases the executive's direct equity stake in the company.
• The transaction was conducted under a Rule 10b5-1 plan, which signifies a pre-scheduled, non-discretionary transaction, enhancing transparency and mitigating concerns about opportunistic insider trading.

Negatives

• The disposition of 535 shares, while for tax withholding purposes, results in a reduction of the executive's immediate direct share count.

Future Outlook

The remaining 67% of the restricted stock units granted on June 9, 2023, are scheduled to vest in equal quarterly installments over the two-year period following June 15, 2024.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, which is a common occurrence across all industries for publicly traded companies. It does not provide information on broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a significant change in company strategy or financial health. The executive's continued equity ownership aligns interests.
• Employees: No direct impact on general employees is indicated.
• Customers/Suppliers/Creditors: No direct impact is indicated.

Next Steps

• Future quarterly vesting installments of the remaining restricted stock units are expected as per the original grant terms.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Rule 10b5-1 Plan, Executive Compensation, Stock Ownership, Chief Legal Officer